Slide 1: Exhibit 99.2
Exhibit 99.2
Slide 2: Immutep LAG-3 Immunotherapy Investor Update June 2018
; @ Immutep LAG-3 IMMUNOTHERAPY Investor Update JUNE 2018 IN THIS ISSUE: MESSAGE FROM THE CEO § OPERATIONAL PROGRESS DADPTNEOING 1ONnaTe Becinancine nionate EB ouiti anv
Slide 3: In This Issue
Investor 02 JUNE IN MESSAGE THIS2018 Update ISSUE: FROM THE CEO OPERATIONAL PROGRESS PARTNERING UPDATE FINANCING UPDATE OUTLOOK
Slide 4: Slide 4
Slide 5: Message from the CEO
« MARC VOIGT Message from the CEO Welcome to the latest edition of Immutep's investor update. | am pleased to report that the team has made a great deal of progress since our last update in December 2017. We have a very active business development pipeline with multiple companies. One specific achie
Slide 6: Message from the CEO
MARC Message Welcome business MSD have More being product IMMUTEP On name [Continued 1the now June, change broadly outside evaluated clinical VOIGT candidates development from to reached members on RINGS the and the across the p. development latest in3] US change CEO the an inTHE the of and estimate
Slide 7: Slide 7
Slide 8: Message from the CEO (continued)
MARC VOIGT Message from the CEO [Continued from p, 2] The NASDAQ bell ringing event was live streamed on Facebook and was broadcast in the U.S. on Fox, CNBC and other channels. If you missed the live stream and broadcast events, you can watch the video we created to mark the occasion, at youtu.be/Uz
Slide 9: Message from the CEO (continued)
MARC Message [Continued the The is Our three Along receive increasingly video NASDAQ bell lead ofwith from VOIGT the ringing product, from wefrom our world’s all created the being bell Australian our ceremony p.efti, CEO 2] ringing largest shareholders. to recognised has mark advanced Securities was
Slide 10: Slide 10
Slide 11: LAG-3 Featured at ASCO Poster Presentations
LAG-3 FEATURED AT ASCO POSTER PRESENTATIONS Immutep was pleased to see that LAG-3 was featured prominently at the recent American Society of Clinical Oncology (ASCO) Annual Meeting, in Chicago, Illinois which took place at the start of June. Our partner Novartis presented two posters, including the
Slide 12: LAG-3 Featured at ASCO Poster Presentations
LAG-3 June. These Immutep meetinglibrary.asco.org/record/165305/abstract The Saint- control very first encouraging Our presentations Luc, rate FEATURED poster was presented partner Université (“DCR”) pleased discussed safety Novartis two were AT was to Catholique posters ASCO profile. see well the 8
Slide 13: Slide 13
Slide 14: LAG-3 Featured at ASCO Poster Presentations (continued)
LAG-3 FEATURED AT ASCO POSTER PRESENTATIONS [Continued from p. 5] The second poster, presented by Dr. Dirix of GZA Hospitals Sint-Augustinus, Antwerp, Belgium, outlined the ongoing AIPAC trial, its design and primary end points. Both of Immutep's poster presentations were well attended and received
Slide 15: LAG-3 Featured at ASCO Poster Presentations (continued)
LAG-3 [Continued The presentations A evaluate INSIGHT immutep.com/files/content/investor/presentation/2018/INSIGHT%20Trial%20ASCO%20 third second poster FEATURED the poster from poster, feasibility were presentation is p.well presented available 5]ATand attended ASCO relating safety at bythe POSTER
Slide 16: Slide 16
Slide 17: Operational Progress
OPERATIONAL PROGRESS Due to recent operational and partner progress, Immutep is pleased to have expanded its clinical devel- opment pipeline considerably, with the addition of our TACTI-002 Phase II trial as well as two new Phase Ila trials from our partner, Novartis. An enlargened version of the be
Slide 18: Operational Progress
OPERATIONAL Due new An Encouraging %20May%20Corporate%20Presentation%20updated.pdf Our measuring treatment This their We [Continued enlargened expect TACTI-mel to Phase trial first recent was dose istumour with updated IIa on delivering TACTI-mel operational recently trials p. and the version Phase
Slide 19: Slide 19
Slide 20: Operational Progress (continued)
OPERATIONAL PROGRESS [Continued from p, 6] AIPAC trial now 50% recruited Immutep's AIPAC trial is progressing well. We are pleased to have reached the mid point in patient recruitment in June, meaning that we have enrolled and commenced dosing of 113 patients across 30 clinical sites situated in Bel
Slide 21: Operational Progress (continued)
OPERATIONAL [Continued Immutep’s 30 AIPAC During trial. patients temporary Possible commercial TACTI-002 Preparations application, Up MSD’s Patients We INSIGHT As IKF detailed Pre-clinical Our clinical mentioned, to project expect first pre-clinical has 120 the Keytruda trial is before now above, pa
Slide 22: Slide 22
Slide 23: Partnering Update
PARTNERING UPDATE Partnering continues to form an integral part of our clinical development strategy. We are pleased to currently have ongoing partnerships in place with GSK, Novartis and Eddingpharm (EOC), along with our collaboration with Merck & Co. Eddingpharm/EOC commissions batches of efti fro
Slide 24: Partnering Update
PARTNERING Partnering with Eddingpharm/EOC Immutep Eddingpharm, The December combination EOC By Kong, GSK GSK, derived immune [Continued way GMP our Pharma completes which Macau, from of suppression. collaboration isbatches 2017, continues background, on pleased holds with Immutep’s anticipates and
Slide 25: Slide 25
Slide 26: Partnering Update (continued)
PARTNERING UPDATE [Continued from p, 8] Novartis doubles number of LAGS25 clinical trials Continuing its development of LAG525, our partner Novartis expanded its clinical development program for this product candidate in April 2018. Building on its two Phase lla clinical trials, it now plans to begi
Slide 27: Partnering Update (continued)
PARTNERING [Continued Continuing plans LAG525 As the Novartis early Earlier CYTLIMIC CYTLIMIC’s Yamaguchi tumors In which April, many exclusive clinical toact in and begin CYTLIMIC doubles recently evaluated of the synergistically the from its University you activity year, worldwide cancer another d
Slide 28: Slide 28
Slide 29: Financing Update and Outlook
FINANCING UPDATE In addition to the operational progress, the Company was also able to successfully conclude an equity raise comer-stoned by two major Australian institutional investors, Australian Ethical Investment and Platinum Asset Management. The raise was also supported by our former Chairman
Slide 30: Financing Update and Outlook
FINANCING In and support The IOUTLOOK We clinical addition also thank Platinum second in hope trial our the to half Asset shareholders, for in the share UPDATE of China progress operational 2018 Management. purchase sponsored will inpartners terms be progress, plan busy by The which ofand EOC again
Slide 31: Slide 31
Slide 32: Company Calendar
COMPANY CALENDER What’s next August 2018 Appendix 4E & 2018 Full Year Statutory Accounts October 2018 ESMO Congress, Munich, Germany - 19 Oct - 23 Oct 2018 November 2018 33rd Annual Meeting SITC 2018; Starts: Nov 7, 2018 - Nov 11, 2018; Walter E. Washington Convention Center, 801 Mt Vernon PI NW, Wa
Slide 33: Company Calendar
COMPANY What’s August Appendix October ESMO 33rd November Annual Congress, next 2018 2018 4E 2018 CALENDER Meeting & 2018 Annual Munich, SITC Full General Year Germany—19 2018; Statutory Meeting Starts: Nov Accounts Oct—23 7, 2018— Oct 2018 Nov 11, 2018; Walter E. Washington Convention Center, 801 M
Slide 34: Slide 34
Slide 35: Immutep Fast Facts
IMMUTEP Fact Facts Listings Australian Securities Exchange (ASX), NASDAQ Stock Codes ASX: IMM, NASDAQ: IMMP Issued Capital —- Ordinary Shares 3.03 billion (as of Jun 14, 2018) Board of Directors Russell J Howard, PhD Non-executive Chairman Mr Marc Voigt Executive Director and Chief Executive Officer
Slide 36: Immutep Fast Facts
Fact IMMUTEP Listings Australian Stock ASX: ~7.2 Issued 3.03 ~ Board Russell Executive Company Mr Grant Non-executive immutep.com A$20.0 Marc Pete Facts billion million Chamberlain Codes IMM, of Capital JA Market Directors Voigt Howard, million Secretary Director Meyers Securities (as NASDAQ: (as–Di
Slide 37: Slide 37
Slide 38: Follow Immutep's Progress
FOLLOW IMMUTEP’S PROGRESS Immutep is dedicated to maintaining consistent and clear communications with our investors. In addition to our quarterly newsletter, we encourage our shareholders to continue following Immutep's progress in a number of ways: GJ immutep.com The company website is a treasure
Slide 39: Follow Immutep's Progress
FOLLOW progress The immutep.com Immutep clinicaltrials.gov such •Our Twitter Facebook LinkedIn AIPAC TACTI-mel company ClinicalTrials.gov repository twitter.com/Immutep in trial is registers linkedin.com/company/857541/ facebook.com/Immutep/ IMMUTEP’S adedicated number trial is website of NCT0261483